drugset / Trial / NCT04071756

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

NCT04071756

Phase 2 Terminated 8 enrolled Dana-Farber Cancer Institute Bayer · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This research is studying the preventative use of topical 0.1% tazarotene gel daily in addition to best practice standards to reduce the development of hand-foot skin reaction (HFSR).

Timeline

Start
2019-12-30
Primary completion
2021-06-12
Completion
2022-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Tazarotene Small molecule 0.1 % Topical